Park National Corp Gilead Sciences, Inc. Transaction History

Park National Corp

$2.82 Billion
Q3 2024

A detailed history of Park National Corp transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Park National Corp holds 4,946 shares of GILD stock, worth $457,900. This represents 0.01% of its overall portfolio holdings.

Number of Shares

4,946

Previous 5,388 8.2%

Holding current value

$457,900

Previous $369,000 12.2%

% of portfolio

0.01%

Previous 0.01%

25 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 01, 2024	SELL	$66.59 - $83.99 $29,432 - $37,123	-442 Reduced 8.2%	4,946 $414,000
Q2 2024 Jul 15, 2024	SELL	$63.15 - $72.88 $26,838 - $30,973	-425 Reduced 7.31%	5,388 $369,000
Q1 2024 Apr 01, 2024	BUY	$71.58 - $87.29 $148,242 - $180,777	2,071 Added 55.34%	5,813 $425,000
Q4 2023 Jan 02, 2024	SELL	$73.27 - $83.09 $25,644 - $29,081	-350 Reduced 8.55%	3,742 $303,000
Q3 2023 Oct 02, 2023	BUY	$73.94 - $80.67 $55,602 - $60,663	752 Added 22.51%	4,092 $306,000
Q1 2023 Apr 03, 2023	SELL	$77.31 - $88.08 $5,257 - $5,989	-68 Reduced 2.0%	3,340 $277,000
Q4 2022 Feb 06, 2023	SELL	$62.32 - $89.47 $6,232 - $8,947	-100 Reduced 2.85%	3,408 $292,000
Q2 2022 Jul 01, 2022	SELL	$57.72 - $65.01 $4,790 - $5,395	-83 Reduced 2.31%	3,508 $216,000
Q1 2022 Apr 01, 2022	SELL	$57.92 - $72.58 $27,975 - $35,056	-483 Reduced 11.86%	3,591 $214,000
Q4 2021 Jan 04, 2022	SELL	$64.88 - $73.64 $12,976 - $14,728	-200 Reduced 4.68%	4,074 $296,000
Q2 2021 Jul 01, 2021	SELL	$63.47 - $69.35 $9,520 - $10,402	-150 Reduced 3.39%	4,274 $295,000
Q1 2021 Apr 01, 2021	SELL	$60.0 - $68.46 $7,560 - $8,625	-126 Reduced 2.77%	4,424 $286,000
Q4 2020 Jan 04, 2021	SELL	$56.65 - $64.55 $55,347 - $63,065	-977 Reduced 17.68%	4,550 $265,000
Q3 2020 Oct 01, 2020	SELL	$62.1 - $78.08 $3,353 - $4,216	-54 Reduced 0.97%	5,527 $349,000
Q2 2020 Jul 01, 2020	SELL	$72.34 - $84.0 $3,327 - $3,864	-46 Reduced 0.82%	5,581 $429,000
Q1 2020 Apr 01, 2020	BUY	$62.63 - $80.22 $6,263 - $8,022	100 Added 1.81%	5,627 $421,000
Q3 2019 Oct 01, 2019	SELL	$62.51 - $69.0 $60,947 - $67,275	-975 Reduced 15.0%	5,527 $350,000
Q2 2019 Jul 01, 2019	SELL	$61.87 - $69.38 $37,431 - $41,974	-605 Reduced 8.51%	6,502 $439,000
Q1 2019 Apr 01, 2019	SELL	$62.53 - $70.05 $17,570 - $19,684	-281 Reduced 3.8%	7,107 $462,000
Q4 2018 Jan 02, 2019	BUY	$60.54 - $79.0 $32,752 - $42,739	541 Added 7.9%	7,388 $463,000
Q3 2018 Oct 02, 2018	SELL	$71.28 - $78.92 $4,276 - $4,735	-60 Reduced 0.87%	6,847 $529,000
Q2 2018 Jul 02, 2018	SELL	$64.88 - $75.68 $48,984 - $57,138	-755 Reduced 9.85%	6,907 $490,000
Q1 2018 Apr 02, 2018	BUY	$72.84 - $88.8 $1,238 - $1,509	17 Added 0.22%	7,662 $577,000
Q4 2017 Jan 02, 2018	SELL	$71.15 - $83.52 $12,878 - $15,117	-181 Reduced 2.31%	7,645 $548,000
Q3 2017 Oct 02, 2017	BUY	$72.11 - $85.47 $564,332 - $668,888	7,826	7,826 $634,000

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Park National Corp , based on Form 13F filings with the SEC.

News

Stay updated on Park National Corp with notifications on news.

Account

Park National Corp Gilead Sciences, Inc. Transaction History